Breaking News Instant updates and real-time market news.

RHHBY

Roche

$0.00

(0.00%)

05:16
03/19/19
03/19
05:16
03/19/19
05:16

Roche announces FDA approval of Tecentriq with chemotherapy for lung cancer

Roche announced that the FDA approved Tecentriq, in combination with chemotherapy, for the initial treatment of adults with extensive-stage small cell lung cancer. "Tecentriq is the first cancer immunotherapy approved for the initial treatment of extensive-stage small cell lung cancer, which is especially difficult to treat," said Sandra Horning, M.D., Roche's Chief Medical Officer and Head of Global Product Development. "Until now, there have been limited treatment advances for this disease, and we are excited to bring a potential new standard of care to patients that has been shown to improve survival compared to chemotherapy."

  • 04

    Apr

  • 17

    Apr

  • 19

    Aug

  • 04

    Nov

RHHBY Roche
$0.00

(0.00%)

02/26/19
BERN
02/26/19
DOWNGRADE
Target $114.5
BERN
Market Perform
Spark Therapeutics downgraded to Market Perform from Outperform at Bernstein
Bernstein analyst Vincent Chen downgraded Spark Therapeutics (ONCE) to Market Perform from Outperform, with a $114.50 price target, after the company and Roche (RHHBY) announced an agreement for the latter to purchase the outstanding shares of Spark at $114.50/share. The analyst thinks "this is likely to be a done deal" as it is hard for him to see the acquisition failing to close. Overall, Chen views the risk of antitrust considerations as limited, and while there are additional players who conceivably could be interested, he suspects they have had a look and Roche was the highest bidder.
02/26/19
JEFF
02/26/19
DOWNGRADE
JEFF
Hold
Spark Therapeutics downgraded to Hold from Buy at Jefferies
Jefferies analyst Michael Yee last night downgraded Spark Therapeutics (ONCE) to Hold while raising his price target for the shares to $114.50 from $85. He believes the buyout by Roche (RHHBY) will close as expected, by Q2. Further, the analyst sees the deal as positive for other gene and cell therapy names, "as interest from large biopharma should persist as the technology matures."
02/27/19
STFL
02/27/19
DOWNGRADE
Target $114.5
STFL
Hold
Spark Therapeutics downgraded to Hold from Buy at Stifel
Stifel analyst Stephen Willey downgraded Spark Therapeutics (ONCE) to Hold from Buy and raised his price target on the stock to $114.50 from $65 to reflect the company's agreement to be acquired by Roche (RHHBY). Willey, who thinks the all-cash offer represents a highly attractive outcome for Spark shareholders and that the company represents a solid strategic fit for Roche, does not expect to see a better competitive offer emerge and expects a timely closing.
03/07/19
WBLR
03/07/19
DOWNGRADE
WBLR
Market Perform
William Blair downgrades Spark after filing points to competitive bid process
William Blair analyst Raju Prasad downgraded Spark Therapeutics (ONCE) to Market Perform from Outperform following the filing of its Schedule 14D-9 form that included a summary on the background of the merger agreement with Roche (RHHBY). The filing describes a competitive process that resulted in the final price and furthers the likelihood of the deal closing, Prasad tells investors.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.